Tert-Buthyl Pitavastatin
| Code | Size | Price |
|---|
| TAR-T13131-500mg | 500mg | £104.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tert-Buthyl Pitavastatin is a metabolite of Pitavastatin, a potent HMG-CoA reductase inhibitor.
CAS:
586966-54-3
Formula:
C29H32FNO4
Molecular Weight:
477.576
Pathway:
Metabolism
Purity:
0.9957
SMILES:
CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)C=Cc1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1
Target:
HMG-CoA Reductase
References
1. Morikawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7(3):138-44.
2. Kanda K, Takahashi R, Yoshikado T, Sugiyama Y. Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. Drug Metab Pharmacokinet. 2018 Jun;33(3):164-172.